Single Chain Antibody Patents (Class 424/135.1)
  • Patent number: 11166953
    Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: November 9, 2021
    Assignee: YALE UNIVERSITY
    Inventors: Dianqing Wu, Qianying Yuan, Abdul Basit, Wenwen Tang
  • Patent number: 11155613
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 26, 2021
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
  • Patent number: 11079381
    Abstract: The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 ?l in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: August 3, 2021
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Gerhard Zugmaier, Peter Kufer, Shilpa Alekar
  • Patent number: 11059906
    Abstract: The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fusion proteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 13, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Paolo G. V. Martini, Madhusudan Natarajan, Patrick Anthony John Haslett, Albert Barnes Seymour
  • Patent number: 11053310
    Abstract: Provided herein are novel anti-EMP2 antibodies useful for the treatment and diagnosis of cancers that express or overexpress EMP2. In one aspect, provided herein is an isolated antibody that binds to Epithelial Membrane Protein 2 (EMP2), that includes heavy chain variable region and a light chain variable region. The heavy chain variable region includes three heavy chain complementary determining regions (HCDRs) and the light chain variable region includes three light chain variable regions (LCDRs). In some embodiments, the sequence of HCDR1 is SEQ ID NO: 11, the sequence of HCDR2 is SEQ ID NO: 12, the sequence of HCDR3 is SEQ ID NO: 13, the sequence of LCDR1 is SEQ ID NO:14, the sequence of LCDR2 is SEQ ID NO: 15, and the sequence of LCDR3 is SEQ ID NO: 16.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 6, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Madhuri Wadehra, Jonathan Braun
  • Patent number: 11041019
    Abstract: The present invention relates to an isolated specific binding molecule which binds human Anx-A1 and comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, wherein each of said CDRs has an amino acid sequence as follows: VLCDR1 has the sequence set forth in SEQ ID NO: 1, 36 or 37; VLCDR2 has the sequence set forth in SEQ ID NO: 2; VLCDR3 has the sequence set forth in SEQ ID NO: 3; VHCDR1 has the sequence set forth in SEQ ID NO: 4; VHCDR2 has the sequence set forth in SEQ ID NO: 5; and VHCDR3 has the sequence set forth in SEQ ID NO: 6; or, for each sequence, an amino acid sequence with at least 85% sequence identity thereto. The specific binding molecule disclosed is therapeutically useful and in particular may be used in therapy for T-cell mediated diseases, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, obsessive compulsive disorder (OCD), and OCD-related diseases, such as anxiety disorders.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 22, 2021
    Assignee: MEDANNEX LTD.
    Inventors: Henry Charles Wilson Hays, Christopher Barry Wood, Tina Caroline Flatau
  • Patent number: 11014977
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 25, 2021
    Assignees: INSERM (Institut National de al Santé et de la Recherche Médicale), Institut Curie, Université Paus Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Patent number: 11013772
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: May 25, 2021
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
  • Patent number: 11000601
    Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 11, 2021
    Assignee: OBI PHARMA, INC.
    Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju Chen, Yi-Chien Tsai, Kai-Chuan Chen
  • Patent number: 10975169
    Abstract: The present disclosure provides methods of treating diabetic retinopathy and ocular inflammatory diseases with anti-ceramide antibodies and antibody fragments.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: April 13, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Richard Kolesnick, Julia Busik
  • Patent number: 10954562
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing and analyte characterization. Such polynucleotide processing may be useful for a variety of applications, including analyte characterization by polynucleotide sequencing. The compositions, methods, systems, and devices disclosed herein generally describe barcoded oligonucleotides, which can be bound to a bead, such as a gel bead, useful for characterizing one or more analytes including, for example, protein (e.g., cell surface or intracellular proteins), genomic DNA, and RNA (e.g., mRNA or CRISPR guide RNAs). Also described herein, are barcoded labelling agents and oligonucleotide molecules useful for “tagging” analytes for characterization.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 23, 2021
    Assignee: 10X GENOMICS, INC.
    Inventors: Phillip Belgrader, Josephine Harada, Tarjei Sigurd Mikkelsen, Katherine Pfeiffer, Serge Saxonov, John R. Stuelpnagel
  • Patent number: 10947319
    Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: March 16, 2021
    Assignee: Zymeworks Inc.
    Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
  • Patent number: 10946093
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: March 16, 2021
    Assignee: Genentech, Inc.
    Inventor: Melissa Junttila
  • Patent number: 10941199
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, Jr., Andrew Polson
  • Patent number: 10934362
    Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: March 2, 2021
    Assignee: AMGEN INC.
    Inventors: Gunasekaran Kannan, Ling Liu, Edward J. Belouski, Cen Xu
  • Patent number: 10899829
    Abstract: EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro-apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections. In addition, anti-EMAPII therapy provides a novel complementary treatment strategy to existing anti-viral and anti-inflammatory approaches.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: January 26, 2021
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Natalia Bogatcheva, Matthias Alexander Clauss, Keith L. March
  • Patent number: 10870699
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: December 22, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Aaron Sato, Ryan Stafford, Junhao Yang
  • Patent number: 10858417
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 10835619
    Abstract: Provided herein is a tumor associated macrophage (TAM)-targeting liposome. The liposome has a lipid bilayer, a targeting agent associated with the lipid bilayer, and a repolarizing agent associated with the lipid bilayer. The targeting agent optionally comprises an antibody or fragment thereof that selectively binds a TAM, whereas the repolarizing agent repolarizes the TAM upon binding of the TAM by the targeting agent. Also provided is a pharmaceutical composition comprising the TAM-targeting liposomes and a method of treating a subject with cancer with the compositions or liposomes described herein.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 17, 2020
    Assignee: Verily Life Sciences LLC
    Inventors: Stephen Morton, Graziella Solinas
  • Patent number: 10781264
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 22, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Patent number: 10780120
    Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 22, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Szu Hua Sharon Lin, Xiaojun Liu, Anne Chew
  • Patent number: 10774156
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 15, 2020
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Patent number: 10738132
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: August 11, 2020
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • Patent number: 10730934
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 4, 2020
    Assignee: Medlmmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Patent number: 10662244
    Abstract: The present invention relates to a method (dosage regimen) for administering a CD3×CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a CD3×CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3×CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 26, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Smith, Samuel Davis, Bindu Varghese, Jessica R. Kirshner, Gavin Thurston, Israel Lowy, Carrie Brownstein
  • Patent number: 10662243
    Abstract: The disclosure provides a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient. The disclosure also provides a method for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising administering doses in a dosing regimen. This dosing regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The Also provided is a pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: May 26, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Bauerle
  • Patent number: 10618972
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 14, 2020
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez
  • Patent number: 10611851
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 7, 2020
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren, Jianlong Lou
  • Patent number: 10603359
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: March 31, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Patent number: 10596257
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: March 24, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Sara Colombetti, Christian Klein, Johannes Sam, Jose Saro, Pablo Umana
  • Patent number: 10588879
    Abstract: A method of treating age-related macular degeneration. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: March 17, 2020
    Assignee: Aurin Biotech Inc.
    Inventors: Patrick L. McGeer, Moonhee Lee
  • Patent number: 10584162
    Abstract: Non-invasive methods are provided herein for diagnosing samples as including a fungus, including fungal infection or contamination, with specific monoclonal antibodies capable of detecting molecules associated with fungi in the sample, such as a biological or environmental sample. These molecules can be identified using various methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), or a lateral flow immunoassay.
    Type: Grant
    Filed: April 23, 2016
    Date of Patent: March 10, 2020
    Assignee: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno
    Inventors: Thomas R. Kozel, Breeana Hubbard, Amanda Burnham-Marusich
  • Patent number: 10526417
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 7, 2020
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • Patent number: 10526411
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 7, 2020
    Assignee: Amgen Inc.
    Inventors: Chadwick Terence King, Gordon Ng, Shaw-Fen Sylvia Hu, Hung Nguyen, Jeannie Jung
  • Patent number: 10519241
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 31, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
  • Patent number: 10519248
    Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: December 31, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
  • Patent number: 10507228
    Abstract: Stapled peptides and methods of using them to inhibit the Kras/Raf interaction are disclosed herein.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 17, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Said M. Sebti, Jianfeng Cai
  • Patent number: 10501553
    Abstract: An anti-EphA2 scFv single-chain antibody binds with high specificity for EphA2 and blocks ephrin binding to Eph-A2. The antibody may be linked with other antigen-targeting domains, such as an anti-CD20 domain, or conjugated with toxins, or used in combination therapy to for treatment of conditions related to overexpression of EphA2. The antibody may also be expressed in vivo by an expression vector that is designed to facilitate such treatment.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: December 10, 2019
    Inventors: Dimitar B Nikolov, Juha Himanen, Urpo Lamminmaki, Hanna Sanmark
  • Patent number: 10487155
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 26, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 10464902
    Abstract: The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: November 5, 2019
    Assignee: Ontogenesis, LLC
    Inventor: Gerald Horn
  • Patent number: 10428155
    Abstract: The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: October 1, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee
  • Patent number: 10400037
    Abstract: The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: September 3, 2019
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
    Inventors: Peter Altevogt, Sandra Lüttgau, Gerhard Moldenhauer, John Hazin
  • Patent number: 10357514
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Patent number: 10316087
    Abstract: Disclosed are a heterodimeric TCR containing artificial interchain disulfide bond between the variable region of ? chain and the constant region of ? chain, a preparing method therefor and a use thereof.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: June 11, 2019
    Assignee: GUANGDONG XIANGXUE LIFE SCIENCES, LTD.
    Inventor: Yi Li
  • Patent number: 10308688
    Abstract: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-?, interferon-?, interferon-?1, interferon-?2 or interferon-?3.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: June 4, 2019
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi
  • Patent number: 10240126
    Abstract: A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem cell(s) having high capacity to differentiate into hematopoietic stem cells and/or hematopoietic progenitor cells, or into blood cells, based on the expression level(s) of one or more genes such as TRIM58, CTSF, FAM19A5, and TCERG1L genes, or on the DNA methylation state(s) of the TRIM58, CSMD1, and/or FAM19A5 gene(s).
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: March 26, 2019
    Assignee: KYOTO UNIVERSITY
    Inventors: Shinya Yamanaka, Yoshinori Yoshida, Masatoshi Nishizawa
  • Patent number: 10174117
    Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Daniel Baty, Patrick Chames, Brigitte Kerfelec, Marc Turini
  • Patent number: 10112990
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 30, 2018
    Assignees: Genentech, Inc., AC Immune SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Patent number: 10077311
    Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 18, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
  • Patent number: 10066023
    Abstract: The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 4, 2018
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert